3-氨基四氢-2H-噻喃-3-羧酸 | 39124-24-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 3-氨基四氢-2H-噻喃-3-羧酸
• 英文名称: 3-aminothiane-3-carboxylic acid
• 英文别名: 3-Amino-tetrahydro-thiopyran-3-carboxylic acid；3-Aminotetrahydro-2H-thiopyran-3-carboxylic acid
• CAS: 39124-24-8
• 化学式: C₆H₁₁NO₂S
• mdl: MFCD08669346
• 分子量: 161.225
• InChiKey: CEBWQLZTRFNDJU-UHFFFAOYSA-N

物化性质

• 沸点：
  334.7±42.0 °C(Predicted)
• 密度：
  1.298±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2.4
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  88.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  3-氨基四氢-2H-噻喃-3-羧酸 在 N-甲基吗啉 、 sodium carbonate 、 氯甲酸异丁酯 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 为溶剂， 反应 31.5h， 生成 benzyl 3-(methylcarbamoyl)thiane-3-ylcarbamate
  参考文献：
  名称：

  非共价相互作用揭示了灵活的单残基模型中的蛋白质链δ构象

  摘要：

  δ构象是蛋白质中的局部二级结构，它暗示主链 N 原子和后续残基的 NH 之间的 π酰胺N-H⋯N 相互作用。迄今为止，其小分子模型仅限于刚性脯氨酸型化合物。我们在此表明​​，在 γ 位具有硫原子的环状氨基酸的衍生物中，特定的侧链/主链 N-H⋯S 相互作用足以稳定δ构象，使其能够与经典的 C5 和 C7 H- 竞争保税构象。

  DOI：

  10.1039/d2cc06658k
• 作为产物：
  描述：

  7-thia-1,3-diazaspiro[4.5]decane-2,4-dione 在 sodium hydroxide 、 盐酸 作用下， 以 水 为溶剂， 以98 %的产率得到3-氨基四氢-2H-噻喃-3-羧酸
  参考文献：
  名称：

  非共价相互作用揭示了灵活的单残基模型中的蛋白质链δ构象

  摘要：

  δ构象是蛋白质中的局部二级结构，它暗示主链 N 原子和后续残基的 NH 之间的 π酰胺N-H⋯N 相互作用。迄今为止，其小分子模型仅限于刚性脯氨酸型化合物。我们在此表明​​，在 γ 位具有硫原子的环状氨基酸的衍生物中，特定的侧链/主链 N-H⋯S 相互作用足以稳定δ构象，使其能够与经典的 C5 和 C7 H- 竞争保税构象。

  DOI：

  10.1039/d2cc06658k

文献信息

• Sulfonylanaloge Spirohydantoine
  作者：B. Unterhalt、A. Scheppan

  DOI：10.3797/scipharm.aut-01-198

  日期：——

  New thiasubstituted sulfonyl analogues of spirohydantoins were synthesized and tested for their anticonvulsant effects. In low concentrations they had no anticonvulsant activities, in higher ones they were neurotoxic.

  新的取代磺酰基螺内酰尿素类似物被合成并测试其抗惊厥效果。在低浓度下，它们没有抗惊厥活性，在较高浓度下，它们具有神经毒性。
• Heterocyclic prolinamide derivatives
  申请人：ORION OPHTHALMOLOGY LLC

  公开号：US11377439B2

  公开（公告）日：2022-07-05

  This invention is directed to novel heterocyclic prolinamide derivatives of Formula (I), and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., (s) controlling, alleviating, or slowing the progression of) of age-related macular degeneration (AMD) and related diseases of the eye. These diseases include dry-AMD, wet-AMD, geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells. The invention disclosed herein is further directed to methods of prevention, slowing the progress of, and treatment of dry-AMD, wet-AMD, and geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells, comprising: administration of a therapeutically effective amount of compound of the invention. The compounds of the invention are inhibitors of HTRA1. Thus, the compounds of the invention are useful in the prevention and treatment of a wide range of diseases mediated (in whole or in part) by HTRA1. The compounds of the invention are also useful for inhibiting HTRA1 protease activity in an eye or locus of an arthritis or related condition.

  本发明涉及式(I)的新型杂环丙氨酰胺衍生物及其药学上可接受的盐、溶液剂、盐的溶解物和原药，可用于预防(如延缓发病或降低发病风险)和治疗(如(s)控制、减轻或延缓进展)老年性黄斑变性(AMD)及相关眼部疾病。这些疾病包括干性黄斑变性、湿性黄斑变性、地理萎缩、糖尿病视网膜病变、早产儿视网膜病变、多形性脉络膜血管病变以及视网膜或感光细胞变性。本文公开的本发明进一步涉及预防、减缓干性-AMD、湿性-AMD 和地理萎缩、糖尿病视网膜病变、早产儿视网膜病变、多形性脉络膜血管病变以及视网膜或感光细胞变性的进展和治疗方法，包括：施用治疗有效量的本发明化合物。本发明化合物是 HTRA1 的抑制剂。因此，本发明化合物可用于预防和治疗由 HTRA1（全部或部分）介导的多种疾病。本发明的化合物还可用于抑制关节炎或相关疾病的眼部或病灶中的 HTRA1 蛋白酶活性。
• HETEROCYCLIC PROLINAMIDE DERIVATIVES
  申请人：ORION OPHTHALMOLOGY LLC

  公开号：US20190322645A1

  公开（公告）日：2019-10-24

  This invention is directed to novel heterocyclic prolinamide derivatives of Formula (I), and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., (s) controlling, alleviating, or slowing the progression of) of age-related macular degeneration (AMD) and related diseases of the eye. These diseases include dry-AMD, wet-AMD, geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells. The invention disclosed herein is further directed to methods of prevention, slowing the progress of, and treatment of dry-AMD, wet-AMD, and geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells, comprising: administration of a therapeutically effective amount of compound of the invention. The compounds of the invention are inhibitors of HTRA1. Thus, the compounds of the invention are useful in the prevention and treatment of a wide range of diseases mediated (in whole or in part) by HTRA1. The compounds of the invention are also useful for inhibiting HTRA1 protease activity in an eye or locus of an arthritis or related condition.
• Non-covalent interactions reveal the protein chain <i>δ</i> conformation in a flexible single-residue model
  作者：Zeynab Imani、Venkateswara Rao Mundlapati、Valérie Brenner、Eric Gloaguen、Katia Le Barbu-Debus、Anne Zehnacker-Rentien、Sylvie Robin、David J. Aitken、Michel Mons

  DOI：10.1039/d2cc06658k

  日期：——

  structure in proteins that implicates a πamide N–H⋯N interaction between a backbone N atom and the NH of the following residue. Small-molecule models thereof have been limited so far to rigid proline-type compounds. We show here that in derivatives of a cyclic amino acid with a sulphur atom in the γ-position, specific side-chain/backbone N–H⋯S interactions stabilize the δ conformation sufficiently to allow

  δ构象是蛋白质中的局部二级结构，它暗示主链 N 原子和后续残基的 NH 之间的 π酰胺N-H⋯N 相互作用。迄今为止，其小分子模型仅限于刚性脯氨酸型化合物。我们在此表明​​，在 γ 位具有硫原子的环状氨基酸的衍生物中，特定的侧链/主链 N-H⋯S 相互作用足以稳定δ构象，使其能够与经典的 C5 和 C7 H- 竞争保税构象。